Bernd Kastler
Algemeen Directeur bij Kastler GmbH
Actieve functies van Bernd Kastler
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Kastler GmbH
 Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Algemeen Directeur | - | - |
| Directeur/Bestuurslid | - | 11-06-2015 |
Loopbaan van Bernd Kastler
Eerdere bekende functies van Bernd Kastler
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | President | - | - |
| BIOTIE THERAPIES CORP | Directeur/Bestuurslid | 01-06-2009 | - |
| Independent Dir/Board Member | 14-11-2008 | - |
Opleiding van Bernd Kastler
| University of Giessen | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 4 |
| Finland | 2 |
Operationeel
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| President | 1 |
Sectoraal
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
elbion AG
elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
Kastler GmbH
Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Finance |
- Beurs
- Insiders
- Bernd Kastler
- Ervaring
